ClinicalTrials.gg
DrugBiological

Secukinumab clinical trials

Also written AIN457, Cosentyx and AIN457A.

studies test it
177
open now
17
in phase 3
84
first study started
2005

How each study uses secukinumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the secukinumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Jan 2015 · COSENTYX · BLA 125504 (FDA, Drugs@FDA)
European Union
14 Jan 2015 · Cosentyx · EMEA/H/C/003729 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Secukinumab
98
Secukinumab 300 mg
12
Secukinumab 150 mg
11
Secukinumab (AIN457)
9
AIN457 300 mg
5

Brand

Cosentyx
23

Development codes

AIN457
75
AIN457A
4

Studies by the year they started

177 studies that test it; most in 2016 (19)

Studies that test secukinumab, by start year
YearStudies
20051
20071
20084
20098
201010
201112
201210
20139
20148
201514
201619
201711
20187
201910
202014
202110
20226
20236
20246
20254
20267

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
15
Phase 2
45
Phase 3
84
Phase 4
35
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 127 · Other 50

Novartis Pharmaceuticals (123) · University of Erlangen-Nürnberg Medical School (3) · Taizhou Mabtech Pharmaceutical Co.,Ltd (2) · Assistance Publique - Hôpitaux de Paris (2) · University Hospital, Ghent (2) · University of California, San Francisco (2) · Icahn School of Medicine at Mount Sinai (2) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2)

Often tested with

Tested in the same studies.

Adalimumab (7) · Ustekinumab (7) · Ixekizumab (7) · Guselkumab (5) · Upadacitinib (4) · Tofacitinib (4) · Canakinumab (4) · Etanercept (4)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test secukinumab.

Studies

Open first, then newest update. How each study uses secukinumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 177

See all 177 studies that test secukinumab →

Given beside what is tested · 6 — secukinumab is usual care or a partner of the new treatment
As the comparator · 10 — what is tested is compared with secukinumab

Codes

What other systems call secukinumab · ClinicalTrials.gg INT005770

  • MeSH (NLM) C555450secukinumabConfirmed NLM, Wikidata
  • UNII (FDA) DLG4EML025SECUKINUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1599788Confirmed FDA, Wikidata
  • Wikidata Q7444755secukinumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152315SecukinumabOne source FDA
  • DrugBank DB09029One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.